Ep 45: KEYNOTE 006 10 year follow-up

Summary

Left siding, Starfishing, and Superstitions! We make a hidden shoutout to Owen and a subtle callout to Zayd ... if you're listening

In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin delve into the Keynote 006 study, exploring its implications for melanoma treatment, long-term follow-up, and patient outcomes. The conversation highlights the importance of understanding CR versus PR in treatment and the need for better data collection on re-treatment. The episode concludes with reflections on the challenges of conducting such extensive research and the importance of collaboration in the field.

Keywords

melanoma, immunotherapy, pembrolizumab, Keynote 006, patient outcomes, superstitions, sleep habits, treatment duration, toxicity, CR vs PR, PFS vs TTP

Takeaways

• The Keynote 006 study provides valuable data on melanoma treatment.
• Long-term follow-up is crucial for understanding treatment efficacy.
• Re-treatment with pembrolizumab can be beneficial for certain patients.
• Understanding the difference between CR and PR is essential in treatment discussions.
• Toxicity profiles of treatments need to be monitored over time.
• Time to progression is a more relevant metric than PFS in some cases.
• Collaboration among researchers is vital for advancing melanoma treatment.

Sound Bites

"It's better to have a CR than have a PR."

"We need to stop doing PFS in long-term follow-ups."

"Patients are dying of other causes, not melanoma."

Chapters

00:00 Introduction and Greetings

03:25 Left side and Starfish

06:43 Superstitions and Their Impact on Behavior

09:35 Keynote 006 Study Overview

12:26 Long-term Follow-up and Treatment Insights

15:38 Re-treatment and Patient Outcomes

18:24 CR vs PR and Treatment Duration

25:07 Final Thoughts and Acknowledgments

28:21 Call to fellows (hearing us, Zayd?)

36:14 PFS v. TTP